?d T Cell Cancer Immunotherapy: Evidence-Based Perspectives for Clinical Translation discusses the current pre-clinical and clinical ?d T cell landscape. The book not only focuses on the promises of what's to come, but also on the challenges faced by the field. Particular attention is given to summarizing recent advances on what is known about relevant areas of ?d T cell biology on summarizing the 'big picture' clinical situation, an up-to-date systematic clinical trial review covering autologous, allogeneic, engineered and non-engineered therapies, and perspectives on the types of cutting-edge gene-engineering that may be required to enhance the effect-size and durability of therapeutic efficacy. Content provides updated and comprehensive insights into the current state of ?d T cell immunotherapy, including discussions on the promise as well as challenges of the field that is of interest to existing translational ?d T cell specialists, the proliferating range of academic scientists and commercial scientists entering the field, as well as clinicians who may encounter ?d T cell immunotherapy in the clinic or are wishing to familiarize themselves with non-canonical lymphocyte immunotherapy.
Table of Contents
1. Overview of current knowledge on human ?d T cell biology 2. ?d T cells and tumors: a two-way interaction 3. ?d T cell 'exhaustion' as an area for therapeutic intervention 4. What is the evidence for ?d T cell suppression by tumors? 5. Synthetic engineering that is optimized for ?d T cells 6. Updated systematic review of ?d T cell clinical trial data 7. Allograft persistence: the next frontier for allogeneic ?d T cell therapy 8. Allogeneic a�T cells, NK cells and ?d T cells: one allogeneic immunotherapy to rule them all? 9. Where next for ?d T cell immunotherapy? A future Perspective
